{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:39:08Z","timestamp":1787002748089,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01591-y","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:39:55Z","timestamp":1785173995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Chenying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-4160","authenticated-orcid":false,"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8360-6395","authenticated-orcid":false,"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-3287","authenticated-orcid":false,"given":"Liangshun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingnong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-5581","authenticated-orcid":false,"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-2460","authenticated-orcid":false,"given":"Yinjun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","volume":"112","author":"T Burmeister","year":"2008","unstructured":"Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel E. Patients\u2019 age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918\u20139.","journal-title":"Blood"},{"key":"1591_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1903\u201330.","journal-title":"Blood"},{"key":"1591_CR3","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024;331:1814\u201323.","journal-title":"JAMA"},{"key":"1591_CR4","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol. 2024;42:4246\u201351.","journal-title":"J Clin Oncol"},{"key":"1591_CR5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. J Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"1591_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood-2024-207892","volume":"144","author":"S Chiaretti","year":"2024","unstructured":"Chiaretti S, Leoncin M, Elia L, Soddu S, Piciocchi A, Matarazzo M, et al. Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820. Blood. 2024;144:835\u2013835.","journal-title":"Blood"},{"key":"1591_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","volume":"18","author":"NJ Short","year":"2025","unstructured":"Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, et al. Molecular characterization and predictors of relapse in patients with Ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab. J Hematol Oncol. 2025;18:55.","journal-title":"J Hematol Oncol"},{"key":"1591_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","volume":"11","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, et al. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol. 2025;11:28\u201335.","journal-title":"JAMA Oncol"},{"key":"1591_CR9","first-page":"906","volume":"111","author":"M Yuan","year":"2026","unstructured":"Yuan M, Zhou L, Li W, Du X, Weng J, Yang L, et al. Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation. Haematologica. 2026;111:906\u201317.","journal-title":"Haematologica"},{"key":"1591_CR10","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-025-02674-8","volume":"39","author":"X Gong","year":"2025","unstructured":"Gong X, Liu W, Liu Y, Fang Q, Gu R, Liu K, et al. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial. Leukemia. 2025;39:1838\u201347.","journal-title":"Leukemia"},{"key":"1591_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/bjh.18975","volume":"202","author":"M Xie","year":"2023","unstructured":"Xie M, Lu Y, Ouyang G, Li X, Shi T, Yang M, et al. Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial. Br J Haematol. 2023;202:1119\u201326.","journal-title":"Br J Haematol"},{"key":"1591_CR12","doi-asserted-by":"publisher","first-page":"11683","DOI":"10.1182\/blood-2022-165879","volume":"140","author":"Y Lou","year":"2022","unstructured":"Lou Y, Xu G, Wang H, Mao L, Tong H, Jin J. Olverembatinib plus low-intensive regimen in frontline therapy for newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single center. Blood. 2022;140:11683\u20134.","journal-title":"Blood"},{"key":"1591_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11:33.","journal-title":"J Hematol Oncol"},{"key":"1591_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1182\/blood-2025-439","volume":"146","author":"S Chiaretti","year":"2025","unstructured":"Chiaretti S, Di Trani M, Skert C, Elia L, Almici G, Della Starza I, et al. First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients. Blood. 2025;146:439.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01591-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01591-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01591-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:25:50Z","timestamp":1785518750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01591-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01591-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Institutional Review Board at the First Affiliated Hospital of Zhejiang University (reference number 2025B IIT No.1110). Approval was obtained by this Institutional Review Board to waive informed consent for this retrospective review. The study was conducted in accordance with the Declaration of Helsinki and other relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"125"}}